NasdaqGM - Nasdaq Real Time Price USD
Oculis Holding AG (OCS)
18.87
+1.14
+(6.43%)
At close: May 2 at 4:00:00 PM EDT
18.87
0.00
(0.00%)
After hours: May 2 at 4:00:11 PM EDT
Research Analysis
Earnings Estimate
| Currency in CHF | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 4 |
| Avg. Estimate | -0.4 | -0.38 | -1.7 | -1.5 |
| Low Estimate | -0.45 | -0.4 | -1.86 | -2.1 |
| High Estimate | -0.38 | -0.36 | -1.44 | -0.69 |
| Year Ago EPS | -0.44 | -0.51 | -2.12 | -1.7 |
Revenue Estimate
| Currency in CHF | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 6 | 5 |
| Avg. Estimate | 217.54k | 219.74k | 736.11k | 31.26M |
| Low Estimate | 150k | 150k | -- | 7.14M |
| High Estimate | 300k | 300k | 1.2M | 74.94M |
| Year Ago Sales | 222k | 245k | 686k | 736.11k |
| Sales Growth (year/est) | -2.01% | -10.31% | 7.30% | 4,146.54% |
Earnings History
| Currency in CHF | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.4 | -0.37 | -0.42 | -0.42 |
| EPS Actual | -0.44 | -0.51 | -0.48 | -0.67 |
| Difference | -0.04 | -0.14 | -0.06 | -0.25 |
| Surprise % | -10.00% | -36.60% | -13.38% | -60.80% |
EPS Trend
| Currency in CHF | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.38 | -1.7 | -1.5 |
| 7 Days Ago | -0.4 | -0.38 | -1.7 | -1.5 |
| 30 Days Ago | -0.4 | -0.38 | -1.7 | -1.5 |
| 60 Days Ago | -0.5 | -0.44 | -1.5 | 0.16 |
| 90 Days Ago | -0.53 | -0.46 | -1.57 | 0.16 |
EPS Revisions
| Currency in CHF | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 1 |
| Up Last 30 Days | 1 | 1 | 2 | -- |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| OCS | 8.33% | 24.84% | 19.83% | 11.91% |
| S&P 500 | 12.40% | 3.81% | 8.28% | 13.79% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 4/17/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/17/2025 |
| Maintains | Chardan Capital: Buy to Buy | 3/13/2025 |
| Maintains | Baird: Outperform to Outperform | 3/13/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/13/2025 |
| Maintains | Chardan Capital: Buy to Buy | 1/7/2025 |
Related Tickers
CAMX.ST Camurus AB (publ)
632.00
+1.77%
LENZ LENZ Therapeutics, Inc.
29.52
+2.22%
BT3.BE Lineage Cell Therapeutics Inc
0.4320
+7.46%
HTD.MU Corcept Therapeutics Inc
63.62
0.00%
25I.SG ImmuPharma PLC
0.0325
-1.52%
328.SG MeiraGTx Holdings PLC
6.45
+4.03%
CLDWW Calidi Biotherapeutics, Inc.
0.0055
-15.38%
PI3.DU Gubra AS
54.00
+9.27%
CAMXs.XC
22Z.SG Zealand Pharma A/S
62.04
+0.81%